



HEALTH RESEARCH BOARD and SCIENCE FOUNDATION IRELAND

Translational Research Awards 2010 (TRA 2010)

Guidance Notes

Key Dates & Times

Application Call	05 February, 2010
Application Closing date (pre-proposal)	26 March 2010, 13:00
Submission of signature pages (pre-proposal)	01 April 2010, 15:00



HRB SFI Translational Research Awards 2010

Table of Contents

1. Introduction.....	3
Objectives.....	3
Scope	4
2. Definitions of Investigators and Collaborators	4
3. Eligibility Criteria of Applicant.....	5
4. Eligibility of Host Institutions.....	7
5. Funding	7
6. Intellectual Property Management.....	8
7. Project Management	8
8. Application Procedure.....	8
Pre-proposal	8
Full proposal	9
9. Guidance on the Application Forms	9
Pre-Proposal	9
Full Proposal	11
10. Application Review Process and Assessment Criteria.....	15
Pre-proposal	15
Full proposal	16
11. Timeframe	18
12. Contacts	19
Appendix I - Definitions of Strategic Areas.....	20
Patient-Oriented Research	20
Medical Devices.....	20
Diagnostics	20
E-health.....	20
Appendix II Translational Continuum.....	21



HRB-SFI Translational Research Awards 2010

Guidance Notes

1. Introduction

The Health Research Board (HRB) and Science Foundation Ireland (SFI) recognise the critical importance of translational research in advancing basic research findings from bench to bedside and have therefore established a new joint initiative in Translational Research.

The HRB has the lead role in bridging the gap between new health research discoveries and the effective translation and implementation of these discoveries into policy and practice in order to achieve specific health service goals. We work with others to build the capacity for health research, create opportunities for researchers, drive the translation of research discoveries into delivering improved healthcare and provide solid evidence to support health research policy. This, in turn, will achieve better outcomes for patients and realise efficiencies in the health service.

SFI advances national scientific progress by awarding grants for research on a competitive basis in those fields of science and engineering that underpin biotechnology (BIO), information and communication technology (ICT), and sustainable energy and energy efficient technologies (ENERGY). SFI funds internationally recognised world class research and recognises that the research excellence of an application is paramount.

The Translational Research Award (TRA) joint initiative aims to support the research funding strategy of both the HRB and SFI (HRB-SFI) with reference to the recently published Health Action Plan 2009¹. The initiative will focus resources in areas which offer the greatest potential for translation into impacts and benefits for health and long term economic development, as well as for more efficient and effective collaboration between academics and healthcare professionals engaged in translational research (e.g. training for academics in skills relevant to translational research). In keeping with the strategic goals of HRB and SFI, these awards will fund investigator-driven research projects with clear milestones and realistic deliverables.

The HRB-SFI is now inviting applications for its 2010 TRAs.

Objectives

The objectives of the HRB-SFI TRA 2010 are:

- To support internationally competitive and innovative research that is specifically concerned with the application of basic research findings into innovative strategies, devices, products or services for the diagnosis, treatment or prevention of human disease.
- To support excellence in research as measured by international merit review.

¹ *Action Plan for Health Research 2009-2013 (Department of Health & Children)*

- To promote new and strengthen existing partnerships between basic and clinical scientists and between academic and industry/charity sectors to expedite the translation of basic research outputs to the clinic and marketplace.
- To lead to improvements in the health and well being of the Irish nation.
- To support milestone-driven projects that are focused on a well defined goal and delivered with efficiency and minimal risk.

Scope

The TRA 2010 is specifically focussed on areas of strategic importance to Ireland's healthcare needs and long term economic development including:

- *Patient-Oriented Research*
- *Medical devices*
- *Diagnostics*
- *E-health*

Definitions of these areas are included within the appendix I. The TRA scheme will focus on early translational research only (see Translational Continuum in appendix II).

The scheme will not fund:

- Applications which are solely or predominately basic biomedical research. For the purposes of the call, basic biomedical research is defined as research conducted to increase the knowledge base and understanding of the physical, chemical and functional mechanisms of life processes and disease but not directed to solving any particular biomedical problem in humans or animals
- Applications seeking to discover new causes or risk factors of disease, biomarkers, drug targets, biomaterials or research tools. Such discoveries will be considered as starting points for this award which would support their application to improve healthcare and benefits for patients
- Applications which are solely for clinical development of therapies or diagnostics i.e. applications beyond the early translational focus of the call, such as late stage clinical trials

Note: For applications including clinical studies that fall within the scope of the EU Clinical Trials Directive, the HRB-SFI cannot take on the role of sponsor so plans for appropriate sponsorship arrangements must be included in the application.

2. Definitions of Investigators and Collaborators

The **Principal Investigator (PI)** will serve as the primary point of contact for the HRB-SFI on the award and during the review process. The PI has primary fiduciary responsibility and accountability for carrying out the research within the funding limits awarded and in accordance with the terms and conditions of the HRB-SFI. Both the PI and Co-PI will be responsible for the scientific and technical direction of the research programme and the submission of reports to the HRB-SFI.

The **Co-PI** has a well-defined, critical and continuing role in the proposed investigation. For the purposes of eligibility, reviewing and monitoring, a Co-PI applying for funding under the HRB-SFI TRA 2010 programme will receive equal evaluation as the PI and will hold equal accountability for the delivery of the proposed research objectives and milestones. In this documentation the terms and conditions for 'PI' and 'Co-PI' are interchangeable.

A **Funded Investigator** will play a significant role in a work-package within the TRA. Funded Investigators will serve under the direction of the PI or Co-PI and may receive funding for items such as running costs and personnel. A Funded Investigator will not receive support towards his/her own salary. The Funded Investigator designation should be a reflection of the level of input of the individual to the research award, and take account of the career stage of the investigator. The Funded Investigator role is optional and we would typically expect no more than 1-2 Funded Investigators for an award of this size.

An **official Collaborator** is an individual who is committed to providing a focused contribution for a specific task. The collaborator will serve under the direction of the PI or Co-PI and will not receive funding through the award. A collaborator may supply samples or kits, may provide training in a technique, enable the use of specific equipment, provide cell lines or antibodies, or may act in an advisory capacity. They can be based in an academic institution, a private enterprise, a healthcare organisation or agency, or come from the charity sector. If involved in genuine scientific collaboration, industrial partners may be included as official collaborators. Industrial collaborators will, in general, be expected to meet their own costs and in cases where they are supplying kits, materials etc they should be provided at no cost to the research teams.

An individual contributing to the research proposal, but not sufficiently involved to warrant listing as an official collaborator or Funded Investigator, can be listed within the text of the research proposal.

CVs must be provided for ALL official collaborators. In addition, each official collaborator must provide a Collaboration Agreement Letter with the full grant application and this must clearly outline the role of that collaborator in the programme of research proposed. The role of the collaborator must also be *referenced* in the main body of the research proposal (For example: *Will the collaborators be supplying samples, data, etc? Will the collaborators be providing training in techniques or the use of equipment? Will the collaborators directly participate in specific work projects? Will collaborators be acting in a purely advisory capacity?*)

3. Eligibility Criteria of Applicant

Applications to this scheme require the pairing of two lead PIs, including an academic investigator and a clinician investigator, in order to develop the project along the translational research continuum to or towards a clinical application. Successful applicants will need to demonstrate an effective transfer of expertise in the direction of bench to bedside.

One applicant and Host Institution (eligible academic institution or clinical setting in the Republic of Ireland) will be nominated as the main contact for all communications. The grant will be administered through the Host Institution of the nominated PI only. The second PI will be referred to as Co-PI for the purposes of this call.

The PI and Co-PI must:

- Have at least **5 years** of independent research experience beyond the PhD, MD or equivalent² by the pre-proposal deadline
- Demonstrate a proven record of internationally recognised independent research accomplishments (as measured by *senior author* publications in high-quality international journals, invited talks at international conferences, or other academic metrics appropriate to the applicant's field. Evidence of enterprise-relevant research activity will also be considered as a measure of an applicant's achievements to date)
- Have demonstrated research independence through securing at least one peer-reviewed, independent research grant as a Lead investigator or as Co-Investigator

² *An equivalent qualification and/or demonstrated research accomplishments may be accepted in exceptional circumstances **and must be approved in advance by HRB-SFI.***

Funded Investigator(s) must:

- Hold a Ph.D/M.D. or equivalent² for at least **3 years** by the pre-proposal deadline
- Must demonstrate a proven record of internationally recognised independent research accomplishments (as measured by *senior author* publications in high quality international journals, invited talks at international conferences, or other academic metrics appropriate to the applicant's field. Evidence of enterprise-relevant research activity will also be considered as a measure of an applicant's achievements to date)

The PI, Co-PI and Funded Investigator are expected to have the capability and authority to mentor and supervise team members, including postgraduate-level students if these are to be included as members of the proposed research team.

In addition, the PI, Co-PI and Funded Investigator(s) must:

- Hold a post (permanent or contract that covers the duration of the award) in an eligible academic institution or clinical setting in the Republic of Ireland **or**
- Be a contract researcher recognised by the Host Institution as an independent investigator who will have an independent office and research space at the Host Institution for which he/she will be fully responsible for at least the duration of the award **or**
- Be an individual who will be recognised by the Host Institution upon receipt of the award as a member of the academic staff or as a contract researcher for at least the duration of the award. The applicant does not necessarily need to be employed by the Host Institution at the time of proposal submission

Host Institution submission confirms that the PI, Co-PI and Funded Investigator (if applicable) meet these criteria and are either members of the academic staff, contract researchers, or awaiting appointment as defined above.

Only one application per investigator will be considered in this round. Applicants who submit an application to the TRA 2010 call are also eligible to apply to other HRB and SFI programmes. Please note that projects that are submitted to other HRB or SFI calls by the same PI/Co-PI **must be distinct and bear no overlap**. However, it is acknowledged that there may be similarities in the subject area/scientific background underpinning applications. PIs/Co-PIs applying simultaneously to other programmes at HRB and/or the SFI may be less competitive if it is deemed that they do not have sufficient capacity and/or experience to justify running two substantial concurrent research programmes.

PIs currently funded under other HRB or SFI award programmes are also eligible to apply. PIs/Co-PIs funded under the HRB or SFI programmes (e.g. HRB CSA or TRA and SFI PI, PICA, PIYRA, SRC or CSET) should note that progress on the existing award will be assessed if they submit an application to the TRA 2010 Programme. Therefore, individuals who have received HRB or SFI programme awards recently may be deemed to be less competitive. Individuals who are funded as either PI or co-PI under these programmes must provide justification at the Full proposal stage for concurrently holding a major HRB or SFI award and a TRA 2010 award.

Applications including collaborations with Industry and Charity sectors are strongly encouraged where these add value to the project, for example through provision of additional funding, reagents, materials, expertise or access to technologies. The terms of collaboration, particularly in relation to industry must be reviewed with your institution's technology transfer office or equivalent. Collaboration arrangements should ensure transparency in the project design and in the analysis of results. Consideration should also be given to issues such as intellectual property rights, access to data and samples etc. See section on IP management for further details.

4. Eligibility of Host Institutions

The Host Institution is the body in charge of the financial and administrative co-ordination of the research project receiving a research grant from the HRB-SFI. Host Institutions must be situated in the Republic of Ireland. The award will be administered by the Host Institution of the nominated PI. Queries regarding eligibility of Host Institutions should be directed to the HRB-SFI prior to submission. The list of approved Host Institutions is located at the following link:

http://www.hrb.ie/fileadmin/Staging/Documents/RSF/PEER/Host_Institution/May_09_List_of_Host_Institutions_for_HRB_Research_Awards.pdf.

5. Funding

HRB-SFI TRA awards will be up to €250,000 direct costs per annum with a maximum award size of €1 million. Funding will be milestone-based i.e. negative results at milestone or failure to meet milestones will result in grant termination. The requested award duration should reflect the nature of the proposed research but should not exceed four years. Please note that the typical duration of a translational research project is 2-3 years.

Funding will initially be granted up to the mid-point of the award (e.g. 2 years for a 4 year award). Projects that successfully meet all milestones up to the mid-point will then undergo a scientific and strategic review. Subject to the completion of a successful review, funding will be granted for the remainder of the award. Please note that continuation of funding at any stage of the award is subject to successfully meeting all milestones and deliverables.

Since this is a milestone-driven award where success will determine a continuum of funding, a full four-years funding for PhD student training cannot be guaranteed. In this regard, the HRB-SFI would like to highlight that this award may be suitable for the training of Masters or postdoctoral researchers in translational research. However, if a PhD student is enrolled on the award, the HEI must guarantee the financial support of the student for the full duration of their doctoral research. It is the sole responsibility of the PI and Co-PI to design an appropriate team structure to ensure that all milestones and deliverables are met.

The budget requested should be appropriate to the proposed work, taking into account the experience and recent research funding record of the applicant(s).

Note: The HRB-SFI does not fund the salary and related costs of academic faculty within research institutions (including buy out from teaching time etc.)

The HRB-SFI funding supports the research programme costs of the PIs and their research groups.

Eligible costs include:

- Relevant research expenses, including equipment where justified, running costs & dissemination
- Only equipment purchases that are directly required for the research and are deemed not to be easily accessible elsewhere in Ireland are appropriate
- Contributions to salaries/stipends for staff hired specifically to carry out the research programme. PI/Co-PI or Funded Investigator salary is not an eligible cost. However, requests for costs associated with securing protected research time of Clinician Investigators will be considered. This does not apply to the role of Funded Investigator
- Access to necessary special facilities which are not available in the host academic or clinical institutions

The following costs are *examples* of ineligible costs: **PI, Co-PI, Funded Investigator or Collaborator salary;** teaching buyout; contingency or miscellaneous costs; maintenance contracts on equipment; hospitality and

entertainment costs; technology transfer or patent costs; conference and workshop organisation costs; journal subscriptions; relocation expenses.

In addition, the HRB-SFI will also make an indirect or overhead **contribution** to the host institution, which is calculated as a percentage of the direct costs (excluding equipment and fees). Overheads are payable as a contribution of 30% to the Host Institution for the indirect costs of hosting the HRB-SFI-funded research programme and are intended to enable the Host Institution to develop internationally competitive research infrastructure and support services.

6. Intellectual Property Management

Information on IP guidelines can be found in Intellectual Property Management Guidelines on the SFI website (http://www.sfi.ie/content/content.asp?section_id=471&language_id=1#ipmg). For awards involving more than one research body, a joint IP agreement should be in place between the relevant institutions. In the absence of a joint IP agreement, the management of any IP remains the responsibility of the host institution.

7. Project Management

To ensure successful delivery of the proposal's objectives, successful applicants will be required to establish appropriate project management systems. During the lifetime of HRB-SFI support successful applications will be required to submit to HRB-SFI Project Start, Quarterly, Milestone, Annual and End of Grant Reports. If a milestone is not met, the project team should submit a remedial plan of action to HRB-SFI as part of the Milestone Report. ***Projects which show negative results at milestones, or which fail to meet milestones, will be terminated, unless acceptable remedial plans are submitted.***

8. Application Procedure

All applications must be made online using the HRB eGrants System.

The TRA 2010 scheme will consist of a two stage application process consisting of:

Stage 1: Open call for submission of pre-proposals

Stage 2: Invitation to selected applicants to submit full proposals

Stage 1: Pre-proposal

TRA 2010 applicants must first submit a pre-proposal application. All applications must be made online using the HRB eGrants system. The purpose of the pre-proposal stage is to ascertain whether the project's aims, objectives and deliverability are internationally competitive, innovative and are appropriate for the scope of the scheme. As outlined in section 9, the strength of the translational element, strategic relevance, applicant expertise and research environment will also be assessed. Successful applicants will be invited to submit a full application.

The HRB-SFI is committed to an open and competitive process underpinned by international peer review. Following an initial eligibility check a Review Committee (which will be composed of international scientists, clinicians and industrial researchers) will consider applications with a view to making final recommendations to the Board of the HRB-SFI. A limited number of applications (approx. 10-12) will then be invited to submit full applications to HRB-SFI.

Individuals may only submit, as PI or Co-PI, one single proposal to an open call of the HRB-SFI TRA Programme. If an applicant submits more than one proposal both applications will be returned without review.

NOTE: Once submitted to eGrants an application cannot be withdrawn and modified for resubmission in the same call regardless of the date of submission.

Stage 2: Full proposal

Selected applicants will be invited to submit a full application. All applications must be made online using the HRB eGrants System. Full applications will be subject to rigorous international peer review, following which a Review Committee, as per the pre-proposal stage, will convene and recommend the best quality proposals.

9. Guidance on the Application Forms

These notes must be read in conjunction with the application form and are designed to help you provide the information required. Applications should be completed in partnership with the Host Institution's Research and Technology Transfer Offices and failure to do so may prejudice your application.

Pre-Proposal

The pre-proposal application form is divided into the following sections:

- PI and Co-PI Profiles and Host Institution Support
- Funded Investigator and Collaborator Profiles (if known)
- Project Description

PI and Co-PI Profiles and Host Institution Support

PI and Co-PI Details

Includes name, contact information and other requested details.

PI and Co-PI role

Outline the role of the PI and Co-PI in the programme of research proposed including percentage of time involved.

PI and Co-PI Publications and Funding Record

You must provide the **ten most relevant publications** in peer-reviewed journals. You must give details of any **past or current grants** held (including HRB and SFI grants) in the past 6 years where the PI/Co-PI has acted as Principal Investigator. You must state if financial support from another funding body has already been provided or is being sought for the same or related research. Include details of any non-exchequer funding awarded in the past 6 years.

Host Institution details

Funded Investigator and Collaborator Profiles (if known)

Funded Investigator details

Includes name, contact information and other requested details.

Funded Investigator role

Outline the role of the Funded Investigator in the programme of research proposed including percentage of time involved.

Funded Investigator Publications and Funding Record

You must provide **ten most relevant publications** in peer-reviewed journals. You must give details of any **past or current grants** held (including HRB and SFI grants) in the past 6 years where the Funded Investigator has acted as Principal Investigator. You must state if financial support from another funding body has already been provided or is being sought for the same or related research. Include details of any non-exchequer funding in past 6 years.

Collaborators

Includes name, role, contact information and other requested details.

Project Description

The Project Description (**1200 words**) should include a brief description of the proposed research addressing the following questions:

- What is the research discovery to be translated including the current state of validation? What are the competing solutions and their developmental status? What is the competitive advantage of the proposed solution?
- What unmet health need will the research address and what is the potential impact on healthcare and the Irish economy?
- What approach or methodology will be used?
- What is the defined endpoint to this project and describe the available resources and facilities that are required to reach this endpoint? Include at least two milestones (one being the project end point)
- What is the current status of any IP relating to the proposed project? Describe any freedom to operate issues that have been identified and how they will be addressed

A maximum of **one** supporting pre-proposal attachment e.g. Figures or Table can be uploaded.

References

A full description of the Publications cited in the Project Description should be provided. You can enter a maximum of 10 publications.

Cochrane Systematic Reviews

You are advised to search the Cochrane Library (www.thecochranelibrary.com) for systematic reviews on a topic(s) that might be relevant to your research proposal. You are asked to complete this section in order to assure the international peer reviewers and grant selection committee that the question you are addressing has not already been carried out and answered and if it has, to justify to the reviewers how you are proposing to add to the existing knowledge and findings (maximum **500 words**).

Cochrane reviews provide systematic, up-to-date summaries of the possible benefits and harms of health care. You can access the Cochrane Library via the HRB website www.hrb.ie.

Sponsorship for Clinical Trial Applications

For applications including clinical studies that fall within the scope of the EU Clinical Trials Directive, the HRB or SFI cannot take on the role of sponsor so plans for appropriate sponsorship arrangements (if known) should be included in the application.

Full Proposal

The full proposal application forms are divided into the following sections:

- Project Description
- IP and Project Management
- Investigator and Collaborator Profiles and Host Institution Support
- Governance & Cost

Project Description

Project Abstract

This should be a succinct summary of the proposed research. The aims and hypotheses of the project should be conveyed with clarity. The objectives of the project and what the work is expected to establish should be described. Ideally it provides a clear synopsis of your proposal and should set the research proposal in context.

Project Lay Summary

This lay summary is similar to the project abstract in that you are asked to describe what you propose to do, why you think it is important to complete this piece of work and how you are actually going to undertake the research. The difference is that it needs to be written in plain English, such that it is easy to understand, and accessible to a broad non-scientific audience. This summary will be used when providing information to the public on the variety of research funded by the HRB-SFI.

Keywords

Please use keywords that specifically describe your area of research.

Project Description

The Project Description (**7500 words**) for the full application should detail:

- The research discovery to be translated including the current state of development/validation. What are the competing solutions and their developmental status? What is the competitive advantage of the proposed solution?
- The unmet medical need the research address and the potential impact on healthcare and the Irish economy
- The specific aims and primary objectives of the project
- Methodological approach (including sample size, power calculations, access to statistical support)
- How the project will achieve its objectives and defined endpoint
- The skills, resources and facilities that are required to reach this endpoint which should be fully justified

Please note that up to two additional files (images, graphs, figures or tables) can be uploaded as part of the Project Description.

Note: The Health Research Board Centre for Support and Training in Analysis and Research (CSTAR) is available for assistance and advice on the methodologies. CSTAR can be found at the following link www.cstar.ie

Note: You are advised to ensure that your application is focused and that sufficient evidence is provided to enable the international peer reviewers and grant selection committees to reach a considered judgement as to the quality of your research proposal, its significance and feasibility.

References

A full description of the Publications cited in the Project Description should be provided. You can enter a maximum of 30 publications.

Cochrane Systematic Reviews

As per pre-proposal.

Sponsorship for Clinical Trial Applications

For applications including clinical studies that fall within the scope of the EU Clinical Trials Directive, the HRB or SFI cannot take on the role of sponsor so plans for appropriate sponsorship arrangements .i.e. Letter clarifying who is going to act as sponsor for this clinical trial study must be included in the application.

IP and Project Management

- Describe how the project will be managed in order to deliver the milestones and key objectives. Include at least two milestones (one being the project end point). ***For each milestone please set out the success criteria that will be used to ascertain whether the milestone has been met. For each success criterion, please specify a quantified target value that you will seek to attain and a quantified acceptable value, which if achieved, would support project progression.***
- Outline Project Management Group membership
- Applicants should provide details of the current status of any IP relating to the proposed project and describe any freedom to operate issues that have been identified and how they will be addressed
- Include a plan for commercial exploitation of outputs. What sources of follow-on funding are available, if any?
- Provide a Gantt chart or alternative graphical overview of the tasks to be undertaken

Investigator and Collaborator Profiles and Host Institution Support

PI, Co-PI and Funded Investigator Details

Includes name, contact information and other requested details

PI, Co-PI and Funded Investigator role

Outline the role of the PI, Co-PI and Funded Investigator in the programme of research proposed including percentage of time involved.

PI, Co-PI and Funded Investigator Publications and Funding Record

You must provide **ten most relevant publications** in peer-reviewed journals. You must give details of any **past or current grants** held (including HRB and SFI grants) within the past 6 years where the applicant has acted as Principal Investigator. You must state if financial support from another funding body has already been provided or is being sought for the same or related research. Include details of any non-exchequer funding awarded in the past 6 years.

Please note that PI and Co-PI profiles provided at the pre-proposal stage can be updated at the full proposal stage. However, there can be no change in the designated PI or Co-PI between the two application stages.

Collaborators

Includes details of all collaborators involved in the research programme. Note that the role of each collaborator must be fully justified. Changes in designated collaborators are permitted between the pre- and full-proposal application stages.

Details of Personnel

Provide full details of all personnel **to be funded** through this project, with names where available. You must demonstrate clearly that the level and expertise of proposed research personnel matches the ambition and scale of the project and that they possess the necessary breadth and skills in all methodological areas required to deliver the proposed programme of work. Clear and explicit justification is also required for the proposed starting

point on the salary scale, particularly for more senior-level positions, and an open and transparent recruitment process must be adhered to.

Host Institution Infrastructure and other Support

Describe the infrastructure, facilities and other support available at the various research sites where the research will be conducted.

Governance & Cost

Project Budget

Provide a summary and justification of the costs associated with the project.

The maximum value of an award is €250,000 per annum (excluding overhead contribution of 30%).

A **full detailed breakdown of costings and justification for all funding** is required for items listed under each subheading. You are strongly advised to seek guidance from the research office/finance office in the host institution before completing this section of the form. The HRB-SFI will not provide additional funding in the case of either under-estimates or over expenditure.

Funds will be provided for the following:

1. Personnel costs	Must be listed for each salaried personnel under each of the following subheadings (a-e):
a) Salary	<p>Gross Annual Salary (including 5% employee pension contribution) negotiated and agreed with host institution. Applicants should use the IUA website scales for the most up-to-date recommended salary scales for researchers (http://www.iua.ie/iua-activities/research.html). Please note employee pension contribution of 5% has already been incorporated into the gross salary figure.</p> <p>Please state the pay scale used and the level and point on the scale. This should be justified accordingly. No annual salary increases will be paid.</p> <p>Please contact the HRB to discuss requests for costs associated with securing protected time of Clinician Investigators.</p> <p>Note: The HRB-SFI does not provide funding for the salary or benefits of academic staff within research institutions who are already in receipt of salary or benefits.</p>
b) Employer’s PRSI	Employer’s PRSI contribution is calculated at 10.75% of gross salary.
c) Employer Pension Contribution	<p><u>As of 1 September 2009, the HRB will cease paying a pension contribution for all awards except where Circular letter 6/2007 applies.</u> Circular Letter 6/2007 states that the pensions contribution of all Public Health Service employees who, on or after 1 June 2007, are granted secondments or periods of special leave with pay to enable them take up appointments with other organisations, including other Public Health Sector organisations, will be increased to 25% of gross pensionable pay. The rate of 25% of gross pensionable pay referred to</p>

	<p>in this context is the pension contributions to be paid by the body to which the employee is seconded – it does not include any pension contributions which employees make themselves. Where no such arrangements are in place, the HRB will not be liable for costs.</p>
d) Student Stipend	<p>The student stipend is €16,000 per annum (tax exempt) as recommended by current IUA scales</p>
e) Student Fees	<p>A contribution to fees for students registered for a higher degree will be paid at the 2008/2009 fee levels for the duration of the award. Please note only personnel in receipt of a stipend are eligible to receive a student fee contribution.</p>
2. Running Costs	<p>For all costs required to carry out the research including materials and consumables, the purchasing, transport or disposal of animals, consultancy, transcription costs, access to special facilities where not available etc.</p> <p>An additional amount of funding for equipment can be included in this section. Only equipment purchases that are directly required for the research and are deemed not to be available elsewhere are appropriate. Links to existing clinical research facilities or other relevant infrastructural resources are encouraged. Stand-alone computers <u>will not</u> be funded. All costs must be inclusive of VAT, where applicable.</p> <p>The following <u>ineligible</u> costs will not be funded: training courses/workshops, inflationary increases, cost of electronic journals, maintenance contracts on equipment, hospitality and entertainment costs; technology transfer or patent costs; conference and workshop organisation costs; journal subscriptions; relocation expenses.</p> <p><u>Note: Please see a list of costs that fall within the overhead contribution.</u></p> <p>http://www.hrb.ie/fileadmin/Staging/Documents/RSF/PEER/Policy_Docs/Grant_policies/Policy_on_Usage_of_HRB_Overheads_240108.pdf</p>
3. Dissemination Costs	<p>Reasonable costs associated with publication of results, seminar/conference attendance (provide details of name and location, where possible) and any other means of communicating/reporting research outcomes.</p>
4. Overhead Contribution	<p>The HRB-SFI will contribute to the indirect costs of the research through an overhead payment of 30% of Total Direct Modified Costs (TDMC excludes student fees, equipment and capital building costs).</p> <p>The following are included in the overhead contribution: recruitment costs, bench fees, animal maintenance, software, contribution to gases, bacteriological media preparation fees, waste fees, bioinformatics access.</p>

Other Funding Sources

Provide details of any other financial support available for this or any other related project in the box provided. Indicate the project title, funding agency and amount of award.

Ethical Approval

Ethical approval is required for all research work funded by the HRB-SFI that involves human participants, human material (including tissue) or animals.

Applicants should allow sufficient time to obtain ethical approval. It is suggested that ethical approval is sought in parallel with submission of an application to the HRB-SFI.

Approval by Host Institution

You must confirm that both the pre-proposal and full applications have been reviewed and/or completed in partnership with your institution's Technology Transfer Office and approved by the Research Office of your Host Institution prior to electronic submission to indicate their formal acceptance and endorsement of the proposal e.g. to ensure salaries are aligned with practices at the Host Institution and any commercial elements have been reviewed by the appropriate expertise.

Submission

Please ensure that you have completed all the relevant sections of the application form. Once you have submitted your application, you cannot edit or remove it.

The deadline for receipt of **pre-proposals** is **Friday 26 March 2010 at 13:00**.

Only applicants who submit a pre-proposal before the deadline of Friday 26 March 2010 at 13:00 will be eligible, if invited, to submit a full proposal.

Full proposals that deviate significantly in content from the pre-proposal will be administratively withdrawn without review.

Signature Page

Signature pages must be signed, dated and sent in hardcopy to **Catherine Gill, Health Research Board, 73 Lower Baggot Street, Dublin 2** no later than **Thursday 01 April at 15:00**. All signatures must be originals. Electronic signatures or faxed copies are not accepted.

Please note that the HRB-SFI will not follow up any supporting documentation related to the application, such as signature page. It is responsibility of the applicant to send the documentation within the stated deadline. If the documentation is not received by the HRB-SFI on time and in the correct format, the application will be deemed ineligible.

10. Application Review Process and Assessment Criteria

The submission of an application to the HRB-SFI shall be construed as consent by the applicant to participate in the peer review process. The HRB-SFI TRA 2010 scheme will use a two phase assessment process. In accordance with this process all eligible applications will be evaluated as follows:

Pre-proposal

Pre-proposal assessment will be carried out by a review committee of distinguished international scientists, clinicians and industrial researchers.

The principal **Criteria for Assessment** of the pre-proposals are:

- Strength of translational element and strategic relevance

- Scientific quality and innovation
- Expertise and research environment

Following this assessment process, a limited number of applicants (approx. 10-12) will be invited to submit full proposal to the HRB-SFI. Successful applicants will be notified by May 2010 and will be invited to submit a proposal by June 2010. Feedback will be provided to all applicants upon completion of Stage 1.

Full proposal

The review process will consist of two stages combining both International Expert Review and Committee Review.

Stage 1 (International Expert Review)

In accordance with the peer-review process used to evaluate proposals submitted to the HRB-SFI, all *eligible* proposals will be forwarded to international experts for evaluation. The HRB-SFI reserves the right to return applications without review where an applicant does not meet HRB-SFI eligibility criteria or where the research programme does not fit with the remit of the HRB-SFI. HRB and SFI will solicit reviews of proposals from at least three peers with expertise in the subject areas of the proposed research. Selection of reviewers shall be at the sole and exclusive discretion of the HRB-SFI.

Reviews received from peers will be collated and forwarded to applicants. Applicants will then be afforded the opportunity to submit a response (*2 page max.*) to reviewers' comments. Applicants will be given a defined period of time in which to respond (*forward notice of dates will be indicated to applicants*).

Reviewers will score all applications based on the same review criteria used for assessment of pre-proposals:

Strength of translational element and strategic relevance

- Fit with the objectives and scope of the call
- The suitability of the development strategy
- Medical need and potential impact on healthcare
- The anticipated outputs, outcomes (e.g. patents), potential payback, impacts of the proposed research and competitive advantage
- Value for money

Scientific quality and innovation

- Clarity of the research question
- The background to the proposed research, justifying the need for work in this area, drawing particularly on existing evidence
- Completeness of the literature review and relevance to study design/research plan
- Clarity of rationale for the research approach and methodology
- Appropriateness of the research design
- Appropriateness of the research methods
- Strength of supporting preliminary data
- Anticipation of difficulties that may be encountered in the research and plans for management
- Originality of the proposed research in terms of hypotheses/research questions addressed, novel technology/methodology and or novel applications of current technology/methodology
- Potential for the creation of new or advancement of knowledge and evidence of benefit to the area covered by the research

Expertise and research environment

- Qualifications of the applicants, including training, experience and independence (relative to career stage)
- Experience of the applicants in the proposed area of research and with the proposed methodology

- Expertise of the applicants, as demonstrated by scientific productivity over the past five years (publications, books, grants held, etc.). Productivity should be considered in the context of the norms for the research area, applicant experience and total research funding of the applicant
- Track record of applicants as demonstrated by the outputs, outcomes and impacts on the health of patients and/or the public arising from previous grants
- Ability to successfully and appropriately develop research findings
- Quality of the plan for using and disseminating the knowledge, potential for promoting innovation and clear plans for the management of intellectual property, where appropriate, to ensure optimal use of the project results for the patient and the healthcare system
- Appropriateness of the team of applicants to carry out the proposed research, in terms of complementarity of expertise and synergistic potential
- Availability and accessibility of suitably qualified personnel, facilities and infrastructure required to conduct the research
- Project management group membership and experience
- Suitability of the environment to conduct the proposed research

Milestones and Deliverables

- Project management plan with clear and realistic milestones and deliverables
- Clearly stated, quantified target values that will be used to measure whether a milestone has been reached
- Availability of the appropriate resources, such as team members and infrastructure, required to meet milestones
- Suitable risk management plan

Stage 2 (Committee Review)

All full applications will proceed to Stage 2 of the review process. A Committee as per Stage 1 will be convened. In addition to briefing material, committee members will receive the original application, international expert reviews and the applicant's response to reviewers' comments. Committee members will assess the inputs of the international peer reviews and the overall merit and priority of applications for the advancement of the treatment and prevention of human disease. Committees will be invited to rank proposals and to make recommendations for applications to be approved for further consideration by the HRB-SFI. When ranking proposals, committee members will give due regard to applicant's career stage and budget requested.

During Stage 2: In addition to the criteria outlined above, the Review Committees will also consider:

- *The applicant's record in securing non-exchequer funding (commensurate with career stage)*
- *The scientific and strategic merits of other proposals within the overall context of the HRB and SFI missions*
- *The availability of current and future funds and value for money*

An executive committee from both funding agencies will agree on the final ranking prior to submitting to Boards for approval.

The HRB-SFI reserves the right to carry out pre-award site visits by international peers where required. Pre-award site visits conducted by HRB and/or SFI staff to examine infrastructure will also occur, where appropriate. Performance of applicants on previous HRB and SFI awards, as determined through site visits and/or annual reports, will be taken into consideration in the decision-making process. *The final funding decisions are at the sole and exclusive discretion of the HRB-SFI.*

The identity of experts who conduct both the external and committee review shall remain confidential and shall not be disclosed to the applicants. However, decisions resulting from the evaluation will be given to the applicant, including all of the external reviews (after Stage 1) and further committee comments, if appropriate, following the conclusion of the HRB-SFI review process.

Reviewers are required to respect the confidentiality of the peer review process, which is designed to protect and preserve the integrity of the HRB-SFI's advisers and processes. Reviewers may not discuss any aspect of the scoring or assessment with applicants or colleagues. The HRB-SFI shall not be liable for the release of information concerning proposals to third parties by those international scientists involved in the merit review process.

The HRB-SFI reserves the right to modify the review process. Applicants will be notified of any relevant modification to the review procedure.

Conflict of interest

Conflict of interest rules *are applied rigorously*. Where a conflict of interest exists, the reviewer is requested to inform the HRB-SFI immediately so that an alternative reviewer may be appointed. International peer reviewers will not provide comments or scores on any application on which they have a conflict of interest.

Reviewers must adhere to high standards of integrity during the peer review process. They must respect the intellectual property of applicants and may not appropriate and use as their own, or disclose to any third party, ideas, concepts or data contained in the applications they review.

A disqualifying conflict of interest may exist if a peer reviewer:

- Was involved in the preparation of the application
- Stands to benefit directly should the proposal be accepted or rejected
- Is in some way related to the Principal Investigator at a personal or professional level
- Is a former supervisor of the Principal Investigator
- Is a collaborator of the Principal Investigator (up to 10 years previously)

A potential conflict of interest may exist in some cases, which is not covered by the disqualifying conflict of interest rules indicated above.

11. Timeframe

5 February 2010	Opening of call
26 March 2010	Deadline for pre proposal submission.
01 April 2010	Deadline for Signature Page submission.
May 2010	Committee Meetings will take place in May 2010 with a view to recommending 10-12 applications to submit a full application to the HRB-SFI by mid-end of June 2010.
June 2010	Deadline for Full proposal submission. Deadline for Signature Page submission.
October 2010	Committee Meetings will take place in late October 2010 with a view to making recommendations to the Board of the HRB-SFI in November 2010.
December 2010	Following Board approval of the recommendations, applicants will be notified of their success by December 2010. Contracts will be issued in January 2011 with a view to beginning the research project from 2011.

12. Contacts

For further information on the Translational Research Awards contact:

Dr Catherine Gill

Project Officer
Health Research Board
73 Lower Baggot Street
Email: cgill@hrb.ie
Tel: +353 1 2345188

Dr. Siobhan Roche

Scientific Programme Manager
Life Sciences Directorate
Science Foundation Ireland
Email: TRA@sfi.ie

Queries regarding the general principles and scope of the call can be directed to either the HRB or SFI. For queries relating to the administration of the call and eGrants please contact the HRB only.

The HRB-SFI reserves the right to reject any application that does not meet the terms of this call. The decision of the HRB-SFI Board in respect of any grant application is final and cannot be appealed or reviewed.

Appendix I - Definitions of Strategic Areas

Patient-Oriented Research Applications submitted under this category should have the patient at the centre of the research goals and generate clinically relevant results. Defined as research conducted with human subjects, or on material of human origin such as tissues, specimens and cognitive phenomena. Projects in this space often include components of applied biomedical work and or/components of health services research in addition to clinical research. Research studies involving *in vivo* or other appropriate pre-clinical models are eligible, as are computational or bio-informatics studies with an emphasis on yielding clinically relevant results. Research should focus on (i) mechanisms of human disease (ii) therapeutic interventions (iii) clinical trials (iv) use of new technologies for the diagnosis, treatment and prevention of disease (v) emotional, social, behavioural and developmental mechanisms of health and disease

Medical Devices A **medical device** is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery. Any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, including the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the manufacturer to be used for human beings.

Diagnostics Products used for the diagnosis of disease or medical condition

E-health Healthcare practice which is supported by electronic processes and communication including services such as electronic health records, telemedicine, consumer health informatics, health knowledge management, virtual healthcare teams, e-health grids, and health information systems. Examples of such research include the development of electronic patient records, development of technology and/or software to support remote patient monitoring and physiological body sensors and development of algorithms/software to enable characterization of disease from medical images.

Appendix II Translational Continuum

